63 results about "Truncated protein" patented technology

The present invention relates to the field of veterinary vaccines, and discloses the development and application of a subunit vaccine for porcine contagious pleuropneumonia. The TbpB-C truncated protein and the AdhE whole protein selected in the antigen protein combination of the vaccine of the present invention are highly homologous in all APP serotypes, and are prepared into subunit vaccines that can provide cross protection to porcine actinobacillus pleuropneumoniae of different serotypes, and the protection rates against APP1 type and APP3 type strains are both 100%. The truncated proteins selected in the antigen protein combination of the present invention are successfully expressed in a soluble form after optimization, and are easy to express and purify in large quantities, thereby reducing production costs. The present invention lays a foundation for the development of an efficient, low-cost, broad-spectrum subunit vaccine for porcine contagious pleuropneumonia, and provides an effective technical means for the prevention and treatment of the disease.

The invention relates to a corn ZmmtRF2a gene mutation marker, an identification primer and application of the corn ZmmtRF2a gene mutation marker in regulation and control of grain development. A natural grain mutant crk5 found in a corn field breeding line selection process is utilized, a target gene ZmmtRF2a causing crk5 grain mutation is obtained through phenotypic analysis, linkage analysis and map-based cloning technologies, the gene encodes a peptide chain release factor 2a for mitochondrial localization, the peptide chain release factor 2a affects the mitochondrial function, and the gene can be used for inducing the mutation of the crk5 grain. The development of corn embryos and endosperm and the accumulation of grain storage substances are regulated and controlled. In crk5, ZmmtRF2a lacks 5th to 7th exons, the encoded truncated protein does not have GGQ and SPF motifs, the motifs are crucial to release activity of RF, mitochondrial binding and termination codon recognition, technical support is provided for utilization of the gene, and a new way is opened up.

The invention relates to the field of biological medicine and aquatic products, and discloses a grass carp IFNf interferon and truncated protein and application thereof in virus resistance or bacterium resistance. The applicant discovers the new subtype IFNf of the grass carp interferon for the first time, the protein coded by the new gene has an efficient antiviral effect, and the derived peptide AMP-G2 of the grass carp interferon has broad-spectrum antibacterial activity. The sensitivity of the grass carp interferon IFNf to grass carp reovirus (GCRV) infection is higher than that of other interferon, and the grass carp interferon IFNf shows obvious antiviral activity on the cellular level and can be used for preparing antiviral drugs. The interferon-derived peptide provided by the invention is a host natural peptide, is small in molecular weight and simple to synthesize, has a remarkable bactericidal effect on various bacteria and fungi, and can be used for preparing broad-spectrum antibacterial agents or antibacterial drugs.

The invention discloses a method for improving the heterologous soluble expression efficiency of cytochrome P450, which is characterized in that plasmids containing coding genes of fungus-derived cytochrome P450 truncated protein and plasmids containing molecular chaperones are jointly transferred into host bacteria to obtain recombinant genetically engineered bacteria for improving the heterologous soluble expression efficiency of cytochrome P450. Through host screening, molecular chaperonin and cytochrome P450 gene modification, the soluble expression efficiency of cytochrome P450 in Escherichia coli is improved, and the problems of poor protein solubility and low expression efficiency when CYP450 is expressed in Escherichia coli at present are solved.

The application relates to the fields of biological medicine and aquaculture, and discloses a zebrafish IFNf interferon truncated protein and application thereof in antibiosis. The zebrafish interferon derivative peptide AMP-Z2 can specifically inhibit fungi. The interferon derivative peptide provided by the application is a host natural peptide, has small molecular weight, is simple to synthesize, has significant bactericidal effects on various bacteria and fungi, and can be used for preparing broad-spectrum antibacterial agents or antibacterial drugs.

The application belongs to the technical field of bioengineering, and particularly relates to application of a riboflavin kinase / FMN adenosine transferase truncated protein and a mutant thereof in FMN synthesis. The application obtains a mutant with improved riboflavin kinase enzyme activity by truncating and mutating RibFM-1, and uses the mutant in FMN production. The FMN yield of the strain containing the truncated protein gene is increased by 49.14%, 33.97%, 43.58%, 22.42%, 76.31% and 113.70% respectively compared with the strain containing the non-truncated gene. It can be seen that the riboflavin kinase / FMN adenosine transferase can significantly improve the yield of FMN after being truncated or mutated, and has a wide application potential in FMN industrial production.

This patent application discloses a recombinant human type II collagen, its preparation method, and its uses. The recombinant human type II collagen of this patent application is a truncated protein of natural human type II collagen, and its amino acid sequence is shown in SEQ ID No: 1. The recombinant human type II collagen of this invention can be expressed in commercial expression systems such as the commercial Pichia pastoris expression system with high expression yields. Furthermore, its tested biological activities (promoting cell proliferation and wound healing) are significantly superior to those of natural human type II collagen, and also significantly superior to other stages of natural human type II collagen.

Disclosed are virus-inspired compositions and preparation methods thereof, where the compositions comprise mutant papillomavirus L1 proteins that spontaneously form capsid backbones and that are conjugated to a peptide comprising an epitope to form immune redirector capsids (IRCs). The epitopes on the peptides are designed to be recognized by a subject's immune system based on the subject's preexisting immune memory developed from the subject's past exposure to the epitope through infection or vaccination. The mutant papillomavirus L1 proteins possess three mutations including an amino-terminal truncation, a carboxy-terminal truncation, and a truncation at helix four. These mutations in the L1 protein yield capsomeres that are form non-canonical T=1 geometry capsid backbones. Disclosed are uses and methods of using the compositions in treating and / or preventing cancers in subjects in need thereof.

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The invention provides an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) Nsp4 protein monoclonal antibody with an inhibition effect and application thereof, a hybridoma cell strain capable of stably secreting the anti-Nsp4 protein monoclonal antibody is prepared, and a new antigen epitope is identified in nsp4 through expressed overlapping truncated protein. Wherein the 123ITEAGELV130 identified by the monoclonal antibody 1C11 shows the potential of universally identifying different types of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus). Meanwhile, expression of Nsp4 protein can be detected in the early stage of PRRSV infection by utilizing the monoclonal antibody 1C11, the monoclonal antibody has a blocking effect on PRRSV positive serum, and it is found that the monoclonal antibody 1C11 can inhibit proliferation of PRRSV in vitro. Research results increase the understanding of PRRSV Nsp4 protein structure and antigen characteristics, and provide a basis for PRRSV early antigen detection.

To provide adeno-associated variants, formulations and methods for pulmonary delivery.SOLUTION: The present disclosure provides variant AAV capsid proteins that confer tropism for lung cells, as well as recombinant adeno-associated viruses comprising the variant AAVs and pharmaceutical compositions comprising the same, and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of lung disorders. (ii) nucleic acids comprising, from 5 ' to 3 ', (a) AAV2 terminal repeats, (b) a promoter, (c) a nucleotide sequence encoding a human cystic fibrosis transmembrane conductance regulator (CFTR) or a biologically active truncated CFTR lacking amino acids 708 to 759 of the human CFTR sequence, (d) a poly-adenylation sequence, and (e) AAV2 terminal repeats.SELECTED DRAWING: None

The invention provides a preparation method and application of a siniperca chuatsi infectious spleen and kidney necrosis virus subunit vaccine. Immunogen of the siniperca chuatsi infectious spleen and kidney necrosis virus subunit vaccine comprises capsid protein MCP of infectious spleen and kidney necrosis virus, envelope protein ORF007L and truncated protein of envelope protein ORF118L; wherein the amino acid sequence of the truncated protein of the capsid protein MCP is as shown in SEQ ID NO. 1; a gene sequence for editing the truncated protein is as shown in SEQ ID NO.4; the amino acid sequence of the truncated protein of the envelope protein ORF007L is as shown in SEQ ID NO. 2; the gene sequence for editing the truncated protein is as shown in SEQ ID NO.5; the amino acid sequence of the truncated protein of the envelope protein ORF118L is as shown in SEQ ID NO. 3; and the gene sequence for editing the truncated protein is as shown in SEQ ID NO.6.

The invention relates to the technical field of biology, in particular to engineered nuclease and application thereof, and particularly, nuclease with small protein molecular weight is obtained by optimizing a Cas protein structural domain. Through modification and optimization of a Cas protein structural domain, it is found that the truncated protein composed of PI, REC-I and WED structural domains at the N end of the V-type Cas protein can give play to the activity of nuclease, and a new path and a new research direction are provided for development and application of nuclease.

Disclosed is a protein comprising no more than three human autoantigenic proteins, wherein a first human autoantigenic protein comprises a truncated myelin oligodendrocyte glycoprotein (MOG) amino acid sequence, a second human autoantigenic protein comprises a myelin basic protein (MBP) amino acid sequence, and a third human autoantigenic protein comprises a truncated proteolipid protein (PLP) amino acid sequence. Also disclosed are related nucleic acids, pharmaceutical compositions, methods of treating a demyelinating disease, and methods of producing the proteins.

Methods and devices to capture and analyze aerosolized particles such as protein biomarkers and their truncated proteoforms characteristic of a disease, including a respiratory disease, in exhaled breath to enable rapid detection of diseases are disclosed. The disclosed methods and systems selectively capture aerosolized particles using a packed bed column. The captured particles are then eluted using one or more solvents and analyzed using devices including mass spectrometry.

The invention provides an IGF2BP3 truncated protein mutant, an overexpression vector and application of the IGF2BP3 truncated protein mutant and belongs to the technical field of genetic engineering, and the IGF2BP3 truncated protein mutant is any one of the following items: 1) a truncated protein mutant I obtained by truncating a KH1-4 structural domain on the basis of IGF2BP3 wild type protein; 2) a truncated protein mutant II obtained by truncating a KH1-2 structural domain on the basis of IGF2BP3 wild type protein; 3) a truncated protein mutant III obtained by truncating a KH3-4 structural domain on the basis of IGF2BP3 wild-type protein.According to the invention, the specific KH structural domain can be systematically disassembled and studied through the obtained different IGF2BP3 truncated protein mutants, and further understanding of the functional mechanism of IGF2BP3 is promoted.

Provided are modified proteins that are functional in RNA-guided DNA cleavage. The proteins include modified IscBs protein that have a modification of the N-terminus or C-terminus, or both. The modifications include a truncation of a PLMP domain of the IscB protein, or a PLMP domain that is relocated to a position of the IscB protein that is not the N-terminus. The modified IscB protein can be provided as a component of a fusion protein. The modified IscB proteins are used with an ωRNA to modify a DNA substrate.

The present invention discloses a bivalent subunit vaccine for porcine contagious pleuropneumonia and porcine pasteurellosis, belonging to the field of veterinary vaccines. The bivalent subunit vaccine of the present invention contains truncated porcine Actinobacillus pleuropneumoniae antigenic proteins ApxⅠAN, ApxⅡAN, ApxⅢAN and OmpD and porcine Pasteurella multocida antigenic proteins PlpE and VacJ, which can provide cross-protection to porcine contagious Actinobacillus pleuropneumoniae and porcine Pasteurella multocida of different serotypes. The truncated proteins selected in the antigen protein combination of the present invention can all be efficiently soluble and expressed, and are easy to mass produce with low cost. The present invention provides an effective technical means for the prevention and treatment of porcine contagious pleuropneumonia and porcine pasteurellosis.

The invention provides a PMFBP1 mutant gene related to azoospermia syndrome and an application of the PMFBP1 mutant gene. The mutant gene is a PMFBP1 gene c.2641Cgt; the protein p.Arg881Ter is subjected to non-sense mutation, so that the encoded protein p.Arg881Ter is truncated, and the function of a sperm head-tail connection device is damaged. The invention also provides a specific Sanger sequencing detection method and a kit of the mutation, which can be used for rapid molecular diagnosis, genetic counseling and assisted reproduction guidance of the disease, and provides a basis for precise medical treatment.

The invention discloses an IgG and IgA antibody detection kit based on porcine rotavirus VP8 protein as well as a preparation method and application of the IgG and IgA antibody detection kit. The kit comprises an elisa plate, positive control serum, negative control serum, an elisa secondary antibody, a sample diluent, a 20-time concentrated washing solution, a substrate solution A, a substrate solution B and a stop solution, wherein the elisa plate is coated with VP8 truncated protein of a porcine rotavirus epidemic strain expressed by mammalian cells. According to the kit, the IgG antibody and the IgA antibody of the porcine rotavirus can be detected at the same time under the condition that only one reagent (enzyme-labeled antibody) is added, and evaluation on the titer of the whole antibody is facilitated. The kit disclosed by the invention is high in sensitivity, high in specificity, good in stability, convenient to operate and relatively high in universality, and has a good market prospect.

The invention discloses a porcine TMEM106a protein polyclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of biology. The pig TMEM106a protein polyclonal antibody is prepared by taking a protein with a sequence as shown in SEQ ID NO.2 as an antigen and carrying out animal immunization. According to the invention, a pig TMEM106a truncated protein segment is utilized to prepare the pig TMEM106a protein polyclonal antibody. The pig TMEM106a protein polyclonal antibody prepared by the invention is strong in specificity and high in titer, and can specifically recognize the TMEM106a protein in pig source cells, so that the pig TMEM106a protein polyclonal antibody can be applied to a pig TMEM106a protein detection reagent or kit. Important tools and technical supports are provided for functional research of the TMEM106a protein on pigs, and the method is suitable for large-scale popularization, production and application.

The invention provides a subunit vaccine composition of a bovine nodular skin disease virus as well as a preparation method and application of the subunit vaccine composition. The subunit vaccine composition comprises subunit ORF61 protein and subunit ORF142 protein of the bovine nodular skin disease virus and a pharmaceutically acceptable adjuvant, the subunit ORF61 protein is an extracellular truncated protein of the ORF61 protein, and the amino acid sequence of the subunit ORF61 protein is as shown in SEQ ID NO. 1; the subunit ORF142 protein is an extracellular truncated protein of the ORF142 protein, and the amino acid sequence of the subunit ORF142 protein is as shown in SEQ ID NO. 2. The subunit vaccine composition for the bovine nodular skin disease virus has excellent immunogenicity and stability of ORF61 protein and ORF142 protein of the bovine nodular skin disease virus, is convenient for stable and efficient secretory expression in engineered cell strains, is high in yield and easy to purify, and has the characteristics of efficient secretory expression, high protein purity, reduced production cost, high safety and the like.

The application provides mRNA based on HEV ORF2 truncated protein, a preparation method and application thereof, the mRNA based on HEV ORF2 truncated protein includes 5'UTR region, SP fragment, 3'UTR region, 3' terminal poly A tail, gene for encoding hepatitis E virus ORF2 truncated protein and 5' cap structure, the hepatitis E virus ORF2 truncated protein is ORF2-239aa protein or ORF2-549aa protein, the nucleotide sequence of the gene for encoding the ORF2-239aa protein is shown as SEQ ID NO.1, the nucleotide sequence of the gene for encoding the ORF2-549aa protein is shown as SEQ ID NO.2, the application has application value in hepatitis E research and vaccine creation, and can greatly promote the transformation application of vaccine.

The present application relates to a truncated IgA protease, a fusion protein comprising the truncated IgA protease (e.g., a fusion protein comprising the truncated IgA protease and an Fc), and use thereof in treating an IgA deposition disease (e.g., IgA nephropathy).

The invention provides an expression cassette, a recombinant expression vector, a genetically engineered bacterium, a construction method, a culture method and an application, and particularly belongs to the technical field of genetic engineering. The invention provides an expression cassette. The expression cassette comprises a SpaC truncated protein gene, an antioxidant enzyme three-enzyme coupling system fusion protein gene and a cytokine fusion protein gene, the expression cassette further comprises a surface display system for presenting the SpaC truncated protein on the surface of the cell; the antioxidant enzyme three-enzyme coupling system fusion protein is fused with catalase, superoxide dismutase and glutathione peroxidase. The cytokine fusion protein is fused with a YebF protein and a trefoil factor 3 protein. The expression cassette provided by the invention has the function of improving the adhesion colonization ability of the EcN strain, can improve the active oxygen scavenging ability of the EcN strain and repair the intestinal epithelial barrier function, is high in safety, and can realize more effective treatment of inflammatory bowel diseases.

The invention relates to the technical field of disease diagnosis, and provides a specific biomarker for granulomatous mastitis and a preparation method and application thereof, the specific biomarker is nicotinamide phosphoribosyltransferase truncated protein, and the amino acid sequence of the specific biomarker is shown as SEQ ID NO. 1. The NAMPT truncated protein is a specific molecule directly related to the GM pathogenesis. The detection result has high directivity, the positive result supports GM diagnosis, and the negative result is helpful for eliminating the GM diagnosis, so that non-iconography objective evidence is provided for differential diagnosis. GM and breast cancer are clearly distinguished in the early stage of diagnosis, and unnecessary anti-cancer treatment or delay of the real illness state is avoided.

This invention discloses a recombinant lactic acid bacteria expressing a truncated avian adenovirus Hexon protein, its construction method, and its applications, belonging to the field of biomedical technology. This invention is the first to construct recombinant lactic acid bacteria strains pNZ8149-FAdV4ΔHexon / NZ3900 and pNZ8149-FAdV8bΔHexon / NZ3900 expressing the truncated avian adenovirus Hexon protein. SDS-PAGE and Western blotting analyses showed that the exogenous genes FADV4-ΔHexon and FADV-8bΔHexon were successfully expressed in *Lactococcus lactis* and exhibited reactivity. Oral immunization of one-day-old chicks showed that oral administration of the recombinant lactic acid bacteria induced humoral and cellular immunity, as well as local mucosal immunity. The results indicate that the recombinant constitutive lactic acid bacteria prepared in this invention can enhance the immunity of chicks.

A method of reducing the risk of a sepsis-induced vascular leak, tissue edema or organ dysfunction is provided. The method involves administering an effective amount of a composition selected from the group consisting of Lipocalin 10 (SEQ ID NO: 1), a truncated Lipocalin 10 (Lcn10) protein having the amino acid sequence SEQ ID NO: 2, Lcn 10-expressing vectors for full length / truncated Lcn10, or combinations thereof to the subject, The method is also useful for reducing the risk of a heart attack-induced cardiac dysfunction, atherosclerosis, inflammatory bowel disease or diabetes-induced cardiomyopathy.

The invention relates to the technical field of medical animal disease models, in particular to a method for establishing a gene point mutation non-human primate model.According to the method, editing is conducted through a CRISPR / Cas9 gene editing system, and finally a non-human primate model carrying CHD8c.3724Cgt is obtained; according to the cynomolgus monkey with T (p.Arg1242Ter) point mutation, different types of point mutations occur at the 3724th basic group of the CHD8 gene, the mutation of T enables arginine (Arg) at the 1242nd site to be replaced by a termination codon to form truncated protein, so that the dosage of CHD8 protein haploid coded by the gene is insufficient. The animal model for simulating human CHD8 mutation related nervous system diseases is constructed and can be used as an ideal research model for researching autism related phenotypes caused by insufficient haplodose, and a foundation is laid for revealing a neurological dysfunction mechanism and exploring a potential treatment strategy.

This application relates to the field of biotechnology, and particularly to a ttc21b gene mutation site and its application; the gene mutation site includes the target site of exon 6 of the ttc21b gene, and the nucleotide sequence of the target site of exon 6 is shown in SEQ ID NO.1; by designing sgRNA targeting exon 6 of the ttc21b gene and using the CRISPR / Cas9 gene editing technology to knockout the ttc21b gene, the translation of the ttc21b gene is prematurely terminated and an abnormal truncated protein is formed, thereby reducing the expression of the ttc21b gene in organisms in the long term.